Stock ACE ASCELIA PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ascelia Pharma AB

Equities

ACE

SE0010573113

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:39 2024-05-31 am EDT 		5-day change 1st Jan Change
10.52 SEK +1.54% Intraday chart for Ascelia Pharma AB +14.72% +212.17%
May. 21 Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024
May. 16 Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 16, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 554.3 1,590 1,005 503 113.8 355.1 - -
Enterprise Value (EV) 1 329.3 1,407 743.4 353.4 91.91 364.6 316.1 315.6
P/E ratio - -15 x -7.81 x -3.96 x - -7.21 x -5.88 x 701 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - - - 13.4 x
EV / Revenue - - - - - - - 11.9 x
EV / EBITDA - -15.1 x -5.39 x -2.4 x -0.83 x -6.95 x -4.55 x -316 x
EV / FCF - -16.4 x -6.38 x -2.82 x -0.72 x -7.68 x -4.72 x 316 x
FCF Yield - -6.11% -15.7% -35.4% -138% -13% -21.2% 0.32%
Price to Book - 6.28 x 3.35 x 2.88 x - 14.4 x 2.49 x 3.81 x
Nbr of stocks (in thousands) 23,489 28,187 33,668 33,668 33,758 33,758 - -
Reference price 2 23.60 56.40 29.85 14.94 3.370 10.52 10.52 10.52
Announcement Date 8/22/19 2/16/21 2/10/22 2/10/23 2/9/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - 26.5
EBITDA 1 - -93.43 -137.9 -147 -110.9 -52.5 -69.5 -1
EBIT 1 -37.39 -93.43 -137.9 -147 -110.9 -52.5 -69.5 -1.5
Operating Margin - - - - - - - -5.66%
Earnings before Tax (EBT) 1 - -99.75 -129.5 -133.2 - -49 -79 -51
Net income 1 - -98.7 -125.9 -131.2 - -49 -79 -51
Net margin - - - - - - - -192.45%
EPS 2 - -3.760 -3.820 -3.770 - -1.460 -1.790 0.0150
Free Cash Flow 1 - -85.92 -116.6 -125.3 -126.8 -47.5 -67 1
FCF margin - - - - - - - 3.77%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 8/22/19 2/16/21 2/10/22 2/10/23 2/9/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA 1 - - - - -52.17 - - - -16.72 -13 -13 -15
EBIT 1 -39.16 -32.57 -32.65 -29.62 -52.17 - -21.36 - -16.72 -13 -13 -15
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) -36.13 -30.03 -23.8 -26.09 -53.24 - - - - - - -
Net income -35.07 -29.08 -22.81 -25.96 -53.38 -40.25 - - - - - -
Net margin - - - - - - - - - - - -
EPS - - - - -1.530 -1.190 -0.6300 - - - - -
Dividend per Share - - - - - - - - - - - -
Announcement Date 2/10/22 5/11/22 8/18/22 11/4/22 2/10/23 8/18/23 11/8/23 2/9/24 5/16/24 - - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 9.5 - -
Net Cash position 1 225 183 262 150 21.9 - 39 39.5
Leverage (Debt/EBITDA) - - - - - -0.181 x - -
Free Cash Flow 1 - -85.9 -117 -125 -127 -47.5 -67 1
ROE (net income / shareholders' equity) - -41.7% -46.3% -53.7% -85.7% -108% -209% 102%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 8.990 8.900 5.190 - 0.7300 4.230 2.760
Cash Flow per Share - -3.260 -3.540 -3.600 - - - -
Capex 1 - - - - - - - -
Capex / Sales - - - - - - - -
Announcement Date 8/22/19 2/16/21 2/10/22 2/10/23 2/9/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ASCELIA PHARMA AB Stock Ascelia Pharma AB
+212.17% 33.71M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACE Stock
  4. Financials Ascelia Pharma AB